Carbinoxamine

Carbinoxamine
Clinical data
AHFS/Drugs.com Monograph
MedlinePlus a606008
Pregnancy
category
  • C
Routes of
administration		 Oral: 4 mg tablet or 4 mg/5 mL liquid
ATC code R06AA08 (WHO)
Legal status
Legal status
  • 4 mg is FDA approved
Pharmacokinetic data
Biological half-life 10 to 20 hours
Identifiers
CAS Number 486-16-8 YesY
PubChem (CID) 2564
IUPHAR/BPS 7139
DrugBank DB00748 YesY
ChemSpider 2466 YesY
UNII VED9E376NC YesY
KEGG D07617 YesY
ChEBI CHEBI:3398 YesY
ChEMBL CHEMBL864 YesY
ECHA InfoCard 100.006.935
Chemical and physical data
Formula C16H19ClN2O
Molar mass 290.788 g/mol
3D model (Jmol) Interactive image
  (verify)

Carbinoxamine (Clistin, Palgic, Rondec, Rhinopront) is a antihistamine and anticholinergic agent. It was first launched in the United States by the McNeil Corporation under the brand name Clistin. It is now available under the brand name Palgic as 4 mg tablets or 4 mg/5 mL liquid. It is approved by the U.S. Food and Drug Administration (FDA) (specifically at the 4 mg dose/strength) for hay fever (a.k.a. allergic rhinitis, SAR and PAR); vasomotor rhinitis; mild urticaria; angioedema, dermatographism and allergic conjunctivitis. Carbinoxamine is a histamine antagonist, specifically an H1-antagonist. The maleic acid salt of the levorotatory isomer is sold as the prescription drug rotoxamine.

Carbinoxamine is available in various countries around the world by itself, combined with decongestants such as pseudoephedrine, and also with other ingredients including paracetamol, aspirin, and codeine.

In June 2006 the FDA announced that more than 120 branded pharmacy products containing carbinoxamine were being illegally marketed and demanded they be removed from the marketplace. This action was precipitated by twenty-one reported deaths in children under the age of two who had been administered carbinoxamine-containing products. Despite the fact that the drug had not been studied in this age group, a multitude of OTC preparations containing carbinoxamine were being marketed for infants and toddlers. At present, all carbinoxamine-containing formulations are approved only for adults or children ages 3 or older.[1]

Carbinoxamine is used in the treatment of severe itching in patients with CD5.

See also

References

  1. ↑


This article is issued from Wikipedia - version of the 6/11/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.